Mark Kris

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Cassileth Barrie R; Rizvi Naiyer; Deng Gary; Yeung K Simon; Vickers Andrew; Guillen Stacey; Woo Derek; Coleton Marci; Kris Mark G
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.
Girard Nicolas; Shen Ronglai; Guo Tianhua; Zakowski Maureen F; Heguy Adriana; Riely Gregory J; Huang James; Lau Christopher; Lash Alex E; Ladanyi Marc; Viale Agnes; Antonescu Cristina R; Travis William D; Rusch Valerie W; Kris Mark G; Pao William
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Pao William; Kris Mark G; Iafrate A John; Ladanyi Marc; Jänne Pasi A; Wistuba Ignacio I; Miake-Lye Ryn; Herbst Roy S; Carbone David P; Johnson Bruce E; Lynch Thomas J
Integration of molecular profiling into the lung cancer clinic.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Mark Kris (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Cassileth Barrie R; Rizvi Naiyer; Deng Gary; Yeung K Simon; Vickers Andrew; Guillen Stacey; Woo Derek; Coleton Marci; Kris Mark G
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.
Cancer chemotherapy and pharmacology 2009;65(1):67-71.
2009: Girard Nicolas; Shen Ronglai; Guo Tianhua; Zakowski Maureen F; Heguy Adriana; Riely Gregory J; Huang James; Lau Christopher; Lash Alex E; Ladanyi Marc; Viale Agnes; Antonescu Cristina R; Travis William D; Rusch Valerie W; Kris Mark G; Pao William
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):6790-9.
2009: Pao William; Kris Mark G; Iafrate A John; Ladanyi Marc; Jänne Pasi A; Wistuba Ignacio I; Miake-Lye Ryn; Herbst Roy S; Carbone David P; Johnson Bruce E; Lynch Thomas J
Integration of molecular profiling into the lung cancer clinic.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(17):5317-22.
2009: Nguyen Don X; Chiang Anne C; Zhang Xiang H-F; Kim Juliet Y; Kris Mark G; Ladanyi Marc; Gerald William L; Massagué Joan
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
Cell 2009;138(1):51-62.
2009: Zhao Binsheng; James Leonard P; Moskowitz Chaya S; Guo Pingzhen; Ginsberg Michelle S; Lefkowitz Robert A; Qin Yilin; Riely Gregory J; Kris Mark G; Schwartz Lawrence H
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.
Radiology 2009;252(1):263-72.
2009: Ettinger David S; Armstrong Debra K; Barbour Sally; Berger Michael J; Bierman Philip J; Bradbury Bob; Ellis Georgianna; Kirkegaard Steve; Kloth Dwight D; Kris Mark G; Lim Dean; Markiewicz Michael Anne; Nabati Lida; Nesheiwat Carli; Rugo Hope S; Sorscher Steven M; Stucky-Marshal Lisa; Todaro Barbara; Urba Susan
Antiemesis. Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(5):572-95.
2009: Zakowski Maureen F; Hussain Sanaa; Pao William; Ladanyi Marc; Ginsberg Michelle S; Heelan Robert; Miller Vincent A; Rusch Valerie W; Kris Mark G
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Archives of pathology & laboratory medicine 2009;133(3):470-7.
2009: Glezerman I; Kris M G; Miller V; Seshan S; Flombaum C D
Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.
Clinical nephrology 2009;71(2):130-9.
2009: Winer Eric; Gralow Julie; Diller Lisa; Karlan Beth; Loehrer Patrick; Pierce Lori; Demetri George; Ganz Patricia; Kramer Barnett; Kris Mark; Markman Maurie; Mayer Robert; Pfister David; Raghavan Derek; Ramsey Scott; Reaman Gregory; Sandler Howard; Sawaya Raymond; Schuchter Lynn; Sweetenham John; Vahdat Linda; Schilsky Richard L;
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(5):812-26.
2009: Riely Gregory J; Rizvi Naiyer A; Kris Mark G; Milton Daniel T; Solit David B; Rosen Neal; Senturk Emir; Azzoli Christopher G; Brahmer Julie R; Sirotnak Francis M; Seshan Venkatraman E; Fogle Margaret; Ginsberg Michelle; Miller Vincent A; Rudin Charles M
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):264-70.
2008: Riely Gregory J; Kris Mark G; Rosenbaum Daniel; Marks Jenifer; Li Allan; Chitale Dhananjay A; Nafa Khedoudja; Riedel Elyn R; Hsu Meier; Pao William; Miller Vincent A; Ladanyi Marc
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5731-4.
2008: Shedden Kerby; Taylor Jeremy M G; Enkemann Steven A; Tsao Ming-Sound; Yeatman Timothy J; Gerald William L; Eschrich Steven; Jurisica Igor; Giordano Thomas J; Misek David E; Chang Andrew C; Zhu Chang Qi; Strumpf Daniel; Hanash Samir; Shepherd Frances A; Ding Keyue; Seymour Lesley; Naoki Katsuhiko; Pennell Nathan; Weir Barbara; Verhaak Roel; Ladd-Acosta Christine; Golub Todd; Gruidl Michael; Sharma Anupama; Szoke Janos; Zakowski Maureen; Rusch Valerie; Kris Mark; Viale Agnes; Motoi Noriko; Travis William; Conley Barbara; Seshan Venkatraman E; Meyerson Matthew; Kuick Rork; Dobbin Kevin K; Lively Tracy; Jacobson James W; Beer David G
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
Nature medicine 2008;14(8):822-7.
2008: Orlow Irene; Park Bernard J; Mujumdar Urvi; Patel Himali; Siu-Lau Puiki; Clas Brian A; Downey Robert; Flores Raja; Bains Manjit; Rizk Nabil; Dominguez Gemma; Jani Jen; Berwick Marianne; Begg Colin B; Kris Mark G; Rusch Valerie W
DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3560-6.
2008: Kris Mark G
Foreword; challenging the 'one-size-fits-all' approach of chemotherapy and radiotherapy for patients with non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2008;60 Suppl 2():S1-2.
2008: Motoi Noriko; Szoke Janos; Riely Gregory J; Seshan Venkatraman E; Kris Mark G; Rusch Valerie W; Gerald William L; Travis William D
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.
The American journal of surgical pathology 2008;32(6):810-27.
2008: Li Allan R; Chitale Dhananjay; Riely Gregory J; Pao William; Miller Vincent A; Zakowski Maureen F; Rusch Valerie; Kris Mark G; Ladanyi Marc
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.
The Journal of molecular diagnostics : JMD 2008;10(3):242-8.
2008: Ettinger David S; Akerley Wallace; Bepler Gerold; Chang Andrew; Cheney Richard T; Chirieac Lucian R; D'Amico Thomas A; Demmy Todd L; Feigenberg Steven J; Figlin Robert A; Govindan Ramaswamy; Grannis Frederic W; Jahan Thierry; Jahanzeb Mohammad; Kessinger Anne; Komaki Ritsuko; Kris Mark G; Langer Corey J; Le Quynh-Thu; Martins Renato; Otterson Gregory A; Patel Jyoti D; Robert Francisco; Sugarbaker David J; Wood Douglas E
Non-small cell lung cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(3):228-69.
2008: Miller Vincent A; Riely Gregory J; Zakowski Maureen F; Li Allan R; Patel Jyoti D; Heelan Robert T; Kris Mark G; Sandler Alan B; Carbone David P; Tsao Anne; Herbst Roy S; Heller Glenn; Ladanyi Marc; Pao William; Johnson David H
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1472-8.
2008: Marks Jenifer L; Broderick Stephen; Zhou Qin; Chitale Dhananjay; Li Allan R; Zakowski Maureen F; Kris Mark G; Rusch Valerie W; Azzoli Christopher G; Seshan Venkatraman E; Ladanyi Marc; Pao William
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(2):111-6.
2008: Rizvi Naiyer A; Riely Gregory J; Azzoli Christopher G; Miller Vincent A; Ng Kenneth K; Fiore John; Chia Gloria; Brower Martin; Heelan Robert; Hawkins Michael J; Kris Mark G
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):639-43.
2008: Azzoli Christopher G; Park Bernard J; Pao William; Zakowski Maureen; Kris Mark G
Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(1):84-93.
2008: Sarkaria Inderpal S; Zakowski Maureen F; Pham Duykhanh; Hezel Michael; Ebright Michael I; Chuai Shaokun; Venkatraman Ennapadam S; Kris Mark G; Rusch Valerie W; Singh Bhuvanesh
Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
The Annals of thoracic surgery 2008;85(1):216-23.
2008: Gralow Julie; Ozols Robert F; Bajorin Dean F; Cheson Bruce D; Sandler Howard M; Winer Eric P; Bonner James; Demetri George D; Curran Walter; Ganz Patricia A; Kramer Barnett S; Kris Mark G; Markman Maurie; Mayer Robert J; Raghavan Derek; Ramsey Scott; Reaman Gregory H; Sawaya Raymond; Schuchter Lynn M; Sweetenham John W; Vahdat Linda T; Davidson Nancy E; Schilsky Richard L; Lichter Allen S;
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):313-25.
2007: Basch Ethan; Iasonos Alexia; Barz Allison; Culkin Ann; Kris Mark G; Artz David; Fearn Paul; Speakman John; Farquhar Rena; Scher Howard I; McCabe Mary; Schrag Deborah
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5374-80.
2007: Weir Barbara A; Woo Michele S; Getz Gad; Perner Sven; Ding Li; Beroukhim Rameen; Lin William M; Province Michael A; Kraja Aldi; Johnson Laura A; Shah Kinjal; Sato Mitsuo; Thomas Roman K; Barletta Justine A; Borecki Ingrid B; Broderick Stephen; Chang Andrew C; Chiang Derek Y; Chirieac Lucian R; Cho Jeonghee; Fujii Yoshitaka; Gazdar Adi F; Giordano Thomas; Greulich Heidi; Hanna Megan; Johnson Bruce E; Kris Mark G; Lash Alex; Lin Ling; Lindeman Neal; Mardis Elaine R; McPherson John D; Minna John D; Morgan Margaret B; Nadel Mark; Orringer Mark B; Osborne John R; Ozenberger Brad; Ramos Alex H; Robinson James; Roth Jack A; Rusch Valerie; Sasaki Hidefumi; Shepherd Frances; Sougnez Carrie; Spitz Margaret R; Tsao Ming-Sound; Twomey David; Verhaak Roel G W; Weinstock George M; Wheeler David A; Winckler Wendy; Yoshizawa Akihiko; Yu Soyoung; Zakowski Maureen F; Zhang Qunyuan; Beer David G; Wistuba Ignacio I; Watson Mark A; Garraway Levi A; Ladanyi Marc; Travis William D; Pao William; Rubin Mark A; Gabriel Stacey B; Gibbs Richard A; Varmus Harold E; Wilson Richard K; Lander Eric S; Meyerson Matthew
Characterizing the cancer genome in lung adenocarcinoma.
Nature 2007;450(7171):893-8.
2007: Pisters Katherine M W; Evans William K; Azzoli Christopher G; Kris Mark G; Smith Christopher A; Desch Christopher E; Somerfield Mark R; Brouwers Melissa C; Darling Gail; Ellis Peter M; Gaspar Laurie E; Pass Harvey I; Spigel David R; Strawn John R; Ung Yee C; Shepherd Frances A;
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5506-18.
2007: Krug Lee M; Milton Daniel T; Jungbluth Achim A; Chen Lin-Chi; Quaia Emilio; Pandit-Taskar Neeta; Nagel Andrew; Jones Jessica; Kris Mark G; Finn Ronald; Smith-Jones Peter; Scott Andrew M; Old Lloyd; Divgi Chaitanya
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(10):947-52.
2007: Liu Vincent; White Dorothy A; Zakowski Maureen F; Travis William; Kris Mark G; Ginsberg Michelle S; Miller Vincent A; Azzoli Christopher G
Pulmonary toxicity associated with erlotinib.
Chest 2007;132(3):1042-4.
2007: Riely Gregory J; Kris Mark G; Zhao Binsheng; Akhurst Tim; Milton Daniel T; Moore Erin; Tyson Leslie; Pao William; Rizvi Naiyer A; Schwartz Lawrence H; Miller Vincent A
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5150-5.
2007: Milton Daniel T; Riely Gregory J; Azzoli Christopher G; Gomez Jorge E; Heelan Robert T; Kris Mark G; Krug Lee M; Pao William; Pizzo Barbara; Rizvi Naiyer A; Miller Vincent A
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Cancer 2007;110(3):599-605.
2007: Azzoli Christopher G; Krug Lee M; Miller Vincent A; Rizvi Naiyer A; Kris Mark G; Dunne Megan; Farmer Amy; Pizzo Barbara; Tyson Leslie; Seeger Teresa; Coleman Barbara; Moore Erin; Lastinger Lauren; Venkatraman Ennapadam; Rudin Charles M
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(7):638-44.
2007: Azzoli Christopher G; Kris Mark G; Pfister David G
Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed.
Journal of the National Cancer Institute 2007;99(11):828-9.
2007: Azzoli Christopher G; Krug Lee M; Gomez Jorge; Miller Vincent A; Kris Mark G; Ginsberg Michelle S; Henry Roxanne; Jones Jessica; Tyson Leslie; Dunne Megan; Pizzo Barbara; Farmer Amy; Venkatraman Ennapadam; Steffen Robert; Sirotnak F M
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2692-8.
2007: Krug Lee M; Heelan Robert T; Kris Mark G; Venkatraman Ennapadam; Sirotnak F M
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(4):317-20.
2007: Fury Matthew G; Solit David B; Su Yungpo Bernard; Rosen Neal; Sirotnak F M; Smith Robert P; Azzoli Christopher G; Gomez Jorge E; Miller Vincent A; Kris Mark G; Pizzo Barbara A; Henry Roxanne; Pfister David G; Rizvi Naiyer A
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2007;59(4):467-75.
2007: Otterson Gregory A; Villalona-Calero Miguel A; Sharma Sunil; Kris Mark G; Imondi Anthony; Gerber Mirjam; White Dorothy A; Ratain Mark J; Schiller Joan H; Sandler Alan; Kraut Michael; Mani Sridhar; Murren John R
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1246-52.
2007: Riely Gregory J; Gadgeel Shirish; Rothman Ivan; Saidman Bruce; Sabbath Kert; Feit Kevie; Kris Mark G; Rizvi Naiyer A
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2007;55(2):181-5.
2007: Ettinger David S; Bierman Philip J; Bradbury Bob; Comish Carli C; Ellis Georgiana; Ignoffo Robert J; Kirkegaard Steve; Kloth Dwight D; Kris Mark G; Lim Dean; Markiewicz Michael Anne; McNulty Robert; Nabati Lidia; Todaro Barbara; Urba Susan; Yowell Sally;
Antiemesis.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(1):12-33.
2007: Ozols Robert F; Herbst Roy S; Colson Yolonda L; Gralow Julie; Bonner James; Curran Walter J; Eisenberg Burton L; Ganz Patricia A; Kramer Barnett S; Kris Mark G; Markman Maurie; Mayer Robert J; Raghavan Derek; Reaman Gregory H; Sawaya Raymond; Schilsky Richard L; Schuchter Lynn M; Sweetenham John W; Vahdat Linda T; Winn Rodger J;
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):146-62.
2007: Marks Jenifer L; McLellan Michael D; Zakowski Maureen F; Lash Alex E; Kasai Yumi; Broderick Stephen; Sarkaria Inderpal S; Pham Duykhanh; Singh Bhuvanesh; Miner Tracie L; Fewell Ginger A; Fulton Lucinda L; Mardis Elaine R; Wilson Richard K; Kris Mark G; Rusch Valerie W; Varmus Harold; Pao William
Mutational analysis of EGFR and related signaling pathway genes in lung Adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
PloS one 2007;2(5):e426.
2006: Zhao Binsheng; Schwartz Lawrence H; Moskowitz Chaya S; Ginsberg Michelle S; Rizvi Naiyer A; Kris Mark G
Lung cancer: computerized quantification of tumor response--initial results.
Radiology 2006;241(3):892-8.
2006: Kris Mark G; Giaccone Giuseppe; Davies Angela; Fukuoka Masahiro; Garfield David H; Jassem Jacek; Quoix Elisabeth A; Sandler Alan B; Scagliotti Giorgio V; Van Meerbeeck Jan P; West Howard
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(9 Suppl):S32-6.
2006: Balak Marissa N; Gong Yixuan; Riely Gregory J; Somwar Romel; Li Allan R; Zakowski Maureen F; Chiang Anne; Yang Guangli; Ouerfelli Ouathek; Kris Mark G; Ladanyi Marc; Miller Vincent A; Pao William
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6494-501.
2006: Basch Ethan; Iasonos Alexia; McDonough Tiffani; Barz Allison; Culkin Ann; Kris Mark G; Scher Howard I; Schrag Deborah
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
The lancet oncology 2006;7(11):903-9.
2006: Hurria Arti; Fleming Mark T; Baker Sharyn D; Kelly Wm Kevin; Cutchall Katie; Panageas Katherine; Caravelli James; Yeung Henry; Kris Mark G; Gomez Jorge; Miller Vincent A; D'Andrea Gabriella; Scher Howard I; Norton Larry; Hudis Clifford
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6100-5.
2006: Milton Daniel T; Riely Gregory J; Pao William; Miller Vincent A; Kris Mark G; Heelan Robert T
Molecular on/off switch.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4940-2.
2006: Milton Daniel T; Azzoli Christopher G; Heelan Robert T; Venkatraman Ennapadam; Gomez Jorge E; Kris Mark G; Krug Lee M; Pao William; Rizvi Naiyer A; Dunne Megan; Miller Vincent A
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Cancer 2006;107(5):1034-41.
2006: Zakowski Maureen F; Ladanyi Marc; Kris Mark G;
EGFR mutations in small-cell lung cancers in patients who have never smoked.
The New England journal of medicine 2006;355(2):213-5.
2006: Ettinger David S; Bepler Gerold; Bueno Raphael; Chang Andrew; Chang Joe Y; Chirieac Lucian R; D'Amico Thomas A; Demmy Todd L; Feigenberg Steven J; Grannis Frederic W; Jahan Thierry; Jahanzeb Mohammad; Kessinger Anne; Komaki Ritsuko; Kris Mark G; Langer Corey J; Le Quynh-Thu; Martins Renato; Otterson Gregory A; Robert Francisco; Sugarbaker David J; Wood Douglas E;
Non-small cell lung cancer clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(6):548-82.
2006: Kris Mark G; Hesketh Paul J; Somerfield Mark R; Feyer Petra; Clark-Snow Rebecca; Koeller James M; Morrow Gary R; Chinnery Lawrence W; Chesney Maurice J; Gralla Richard J; Grunberg Steven M
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):2932-47.
2006: Fury Matthew G; Krug Lee M; Azzoli Christopher G; Sharma Sunil; Kemeny Nancy; Wu Nian; Kris Mark G; Rizvi Naiyer A
A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
Cancer chemotherapy and pharmacology 2006;57(5):671-7.
2006: Pham DuyKhanh; Kris Mark G; Riely Gregory J; Sarkaria Inderpal S; McDonough Tiffani; Chuai Shaokun; Venkatraman Ennapadam S; Miller Vincent A; Ladanyi Marc; Pao William; Wilson Richard K; Singh Bhuvanesh; Rusch Valerie W
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1700-4.
2006: Moryl Natalie; Obbens Eugenie A; Ozigbo Obinna Henry; Kris Mark G
Analgesic effect of gefitinib in the treatment of non-small cell lung cancer.
The journal of supportive oncology 2006;4(3):111.
2006: Riely Gregory J; Pao William; Pham Duykhanh; Li Allan R; Rizvi Naiyer; Venkatraman Ennapadam S; Zakowski Maureen F; Kris Mark G; Ladanyi Marc; Miller Vincent A
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):839-44.
2006: Herbst Roy S; Bajorin Dean F; Bleiberg Harry; Blum Diane; Hao Desirée; Johnson Bruce E; Ozols Robert F; Demetri George D; Ganz Patricia A; Kris Mark G; Levin Bernard; Markman Maurie; Raghavan Derek; Reaman Gregory H; Sawaya Raymond; Schuchter Lynn M; Sweetenham John W; Vahdat Linda T; Vokes Everett E; Winn Rodger J; Mayer Robert J;
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):190-205.
2005: Kris Mark
New approaches in the management of lung cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3 Suppl 1():S22-4.
2005: Krug Lee M; Miller Vincent A; Patel Jyoti; Crapanzano John; Azzoli Christopher G; Gomez Jorge; Kris Mark G; Heelan Robert T; Pizzo Barbara; Tyson Leslie; Sheehan Christine; Ross Jeffrey S; Venkatraman Ennapadam
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Cancer 2005;104(10):2149-55.
2005: Hurria Arti; Gupta Supriya; Zauderer Marjorie; Zuckerman Enid L; Cohen Harvey J; Muss Hyman; Rodin Miriam; Panageas Katherine S; Holland Jimmie C; Saltz Leonard; Kris Mark G; Noy Ariela; Gomez Jorge; Jakubowski Ann; Hudis Clifford; Kornblith Alice B
Developing a cancer-specific geriatric assessment: a feasibility study.
Cancer 2005;104(9):1998-2005.
2005: Bell Daphne W; Lynch Thomas J; Haserlat Sara M; Harris Patricia L; Okimoto Ross A; Brannigan Brian W; Sgroi Dennis C; Muir Beth; Riemenschneider Markus J; Iacona Renee Bailey; Krebs Annetta D; Johnson David H; Giaccone Giuseppe; Herbst Roy S; Manegold Christian; Fukuoka Masahiro; Kris Mark G; Baselga José; Ochs Judith S; Haber Daniel A
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):8081-92.
2005: Kris Mark G
How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.
The oncologist 2005;10 Suppl 2():23-9.
2005: Livingston P O; Hood C; Krug L M; Warren N; Kris M G; Brezicka T; Ragupathi G
Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
Cancer immunology, immunotherapy : CII 2005;54(10):1018-25.
2005: Herbst Roy S; Prager Diane; Hermann Robert; Fehrenbacher Lou; Johnson Bruce E; Sandler Alan; Kris Mark G; Tran Hai T; Klein Pam; Li Xin; Ramies David; Johnson David H; Miller Vincent A;
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5892-9.
2005: Omuro Antonio M P; Kris Mark G; Miller Vincent A; Franceschi Enrico; Shah Neelam; Milton Daniel T; Abrey Lauren E
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Cancer 2005;103(11):2344-8.
2005: Rosenzweig Kenneth E; Fox Jana L; Yorke Ellen; Amols Howard; Jackson Andrew; Rusch Valerie; Kris Mark G; Ling Clif C; Leibel Steven A
Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
Cancer 2005;103(10):2118-27.
2005: Krug Lee M; Crapanzano John P; Azzoli Christopher G; Miller Vincent A; Rizvi Naiyer; Gomez Jorge; Kris Mark G; Pizzo Barbara; Tyson Leslie; Dunne Megan; Heelan Robert T
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Cancer 2005;103(10):2128-31.
2005: Cella David; Herbst Roy S; Lynch Thomas J; Prager Diane; Belani Chandra P; Schiller Joan H; Heyes Anne; Ochs Judith S; Wolf Michael K; Kay Andrea C; Kris Mark G; Natale Ronald B
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2946-54.
2005: Hollen P J; Gralla R J; Kris M G; McCoy S; Donaldson G W; Moinpour C M
A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life?
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2005;14(3):837-47.
2005: Solit David B; She Yuhong; Lobo Jose; Kris Mark G; Scher Howard I; Rosen Neal; Sirotnak Frank M
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1983-9.
2005: Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
PLoS medicine 2005;2(3):e73.
2005: Kris Mark G; Hesketh Paul J; Herrstedt Jorn; Rittenberg Cynthia; Einhorn Lawrence H; Grunberg Steven; Koeller Jim; Olver Ian; Borjeson Sussanne; Ballatori Enzo
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(2):85-96.
2005: Pao William; Wang Theresa Y; Riely Gregory J; Miller Vincent A; Pan Qiulu; Ladanyi Marc; Zakowski Maureen F; Heelan Robert T; Kris Mark G; Varmus Harold E
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
PLoS medicine 2005;2(1):e17.
2005: Milton Daniel T; Kris Mark G; Gomez Jorge E; Feinstein Marc B
Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(1):70-2.
2005: Shah Neelam T; Kris Mark G; Pao William; Tyson Leslie B; Pizzo Barbara M; Heinemann Murk-Hein; Ben-Porat Leah; Sachs Dana L; Heelan Robert T; Miller Vincent A
Practical management of patients with non-small-cell lung cancer treated with gefitinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):165-74.
2005: Laurie Scott A; Miller Vincent A; Grant Stefan C; Kris Mark G; Ng Kenneth K
Phase I study of green tea extract in patients with advanced lung cancer.
Cancer chemotherapy and pharmacology 2005;55(1):33-8.
2004: Sarkaria Inderpal S; Pham DuyKhanh; Ghossein Ronald A; Talbot Simon G; Hezel Michael; Dudas Maria E; Ebright Michael I; Chuai Shaokun; Memoli Natalie; Venkatraman Ennapadam S; Miller Vincent A; Kris Mark G; Zakowski Maureen F; Rusch Valerie W; Singh Bhuvanesh
SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma.
The Annals of thoracic surgery 2004;78(5):1734-41.
2004: Ettinger David S; Bierman Philip J; Bradbury Bob; Ellis Georgiana; Ignoffo Robert J; Kirkegaard Steve; Kloth Dwight; Krauss Amy; Kris Mark G; Lim Dean; Markiewicz Michael Anne; McNulty Robert; Noonan Kim; Stucky-Marshall Lisa; Todaro Barbara; Urba Susan; Yowell Sally;
Antiemesis clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(5):470-90.
2004: Krug Lee M; Ragupathi Govind; Hood Chandra; Kris Mark G; Miller Vincent A; Allen Jennifer R; Keding Stacy J; Danishefsky Samuel J; Gomez Jorge; Tyson Leslie; Pizzo Barbara; Baez Valerie; Livingston Philip O
Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6094-100.
2004: Pao William; Miller Vincent; Zakowski Maureen; Doherty Jennifer; Politi Katerina; Sarkaria Inderpal; Singh Bhuvanesh; Heelan Robert; Rusch Valerie; Fulton Lucinda; Mardis Elaine; Kupfer Doris; Wilson Richard; Kris Mark; Varmus Harold
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(36):13306-11.
2004: Pao William; Miller Vincent A; Venkatraman Ennapadam; Kris Mark G
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
Journal of the National Cancer Institute 2004;96(15):1117-9.
2004: Talbot Simon G; O-charoenrat Pornchai; Sarkaria Inderpal S; Ghossein Ronald; Reddy Pabbathi; Ngai Ivan; Cordeiro Christina N; Wong Richard J; Kris Mark G; Rusch Valerie W; Singh Bhuvanesh
Squamous cell carcinoma related oncogene regulates angiogenesis through vascular endothelial growth factor-A.
Annals of surgical oncology 2004;11(5):530-4.
2004: Patel Jyoti D; Bach Peter B; Kris Mark G
Lung cancer in US women: a contemporary epidemic.
JAMA : the journal of the American Medical Association 2004;291(14):1763-8.
2004: Miller Vincent A; Kris Mark G; Shah Neelam; Patel Jyoti; Azzoli Christopher; Gomez Jorge; Krug Lee M; Pao William; Rizvi Naiyer; Pizzo Barbara; Tyson Leslie; Venkatraman Ennapadam; Ben-Porat Leah; Memoli Natalie; Zakowski Maureen; Rusch Valerie; Heelan Robert T
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(6):1103-9.
2004: Krug Lee M; Ragupathi Govind; Ng Kenneth K; Hood Chandra; Jennings Harold J; Guo Zhongwu; Kris Mark G; Miller Vincent; Pizzo Barbara; Tyson Leslie; Baez Valerie; Livingston Philip O
Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):916-23.
2004: Pao William; Miller Vincent A; Kris Mark G
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).
Seminars in cancer biology 2004;14(1):33-40.
2003: Hurria Arti; Kris Mark G
Management of lung cancer in older adults.
CA: a cancer journal for clinicians 2003;53(6):325-41.
2003: Kris Mark G
Why do we need another antiemetic? Just ask.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(22):4077-80.
2003: Kris Mark G; Natale Ronald B; Herbst Roy S; Lynch Thomas J; Prager Diane; Belani Chandra P; Schiller Joan H; Kelly Karen; Spiridonidis Harris; Sandler Alan; Albain Kathy S; Cella David; Wolf Michael K; Averbuch Steven D; Ochs Judith J; Kay Andrea C
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
JAMA : the journal of the American Medical Association 2003;290(16):2149-58.
2003: She Yuhong; Lee Fei; Chen Jing; Haimovitz-Friedman Adriana; Miller Vincent A; Rusch Valerie R; Kris Mark G; Sirotnak F M
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3773-8.
2003: Azzoli Christopher G; Miller Vincent A; Ng Kenneth K; Krug Lee M; Hensley Martee L; O'Reilly Eileen M; Muller Raymond J; Kris Mark G
Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature.
American journal of clinical oncology 2003;26(3):247-51.
2003: Krug Lee M; Azzoli Christopher G; Kris Mark G; Miller Vincent A; Khokhar Nushmia Z; Tong William; Ginsberg Michelle S; Venkatraman Ennapadam; Tyson Leslie; Pizzo Barbara; Baez Valerie; Ng Kenneth K; Sirotnak F M
10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2072-8.
2003: Miller Vincent A; Johnson David H; Krug Lee M; Pizzo Barbara; Tyson Leslie; Perez Wendy; Krozely Peggy; Sandler Alan; Carbone David; Heelan Robert T; Kris Mark G; Smith Robert; Ochs Judith
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(11):2094-100.
2003: Azzoli Christopher G; Miller Vincent A; Ng Kenneth K; Krug Lee M; Spriggs David R; Tong William P; Riedel Elyn R; Kris Mark G
A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2003;51(6):493-8.
2003: Bach Peter B; Kattan Michael W; Thornquist Mark D; Kris Mark G; Tate Ramsey C; Barnett Matt J; Hsieh Lillian J; Begg Colin B
Variations in lung cancer risk among smokers.
Journal of the National Cancer Institute 2003;95(6):470-8.
2003: Patel Jyoti D; Krug Lee M; Azzoli Christopher G; Gomez Jorge; Kris Mark G; Miller Vincent A
Targeting lethal minimal residual disease in small cell lung cancer.
Seminars in oncology 2003;30(1):79-85.
2003: Krug Lee M; Miller Vincent A; Filippa Daniel A; Venkatraman Ennapadam; Ng Kenneth K; Kris Mark G
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.
Lung cancer (Amsterdam, Netherlands) 2003;39(2):139-43.
2002: Kris Mark G; Tonato Maurizio
New approaches in the treatment of non-small cell lung cancer: taxanes in the treatment of NSCLC: pathways to progress.
Lung cancer (Amsterdam, Netherlands) 2002;38 Suppl 4():1-3.
2002: Ebright Michael I; Zakowski Maureen F; Martin Jocelyne; Venkatraman Ennapadam S; Miller Vincent A; Bains Manjit S; Downey Robert J; Korst Robert J; Kris Mark G; Rusch Valerie W
Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.
The Annals of thoracic surgery 2002;74(5):1640-6; discussion 1646-7.
2002: Downey Robert J; Ng Kenneth K; Kris Mark G; Bains Manjit S; Miller Vincent A; Heelan Robert; Bilsky Mark; Ginsberg Robert; Rusch Valerie W
A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.
Lung cancer (Amsterdam, Netherlands) 2002;38(2):193-7.
2002: Koeller Jim M; Aapro Matti S; Gralla Richard J; Grunberg Steven M; Hesketh Paul J; Kris Mark G; Clark-Snow Rebecca A
Antiemetic guidelines: creating a more practical treatment approach.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2002;10(7):519-22.
2002: Laurie Scott A; Kris Mark G; Portlock Carol S; Rosenzweig Kenneth E; Miller Vincent A; Krug Lee M; Rusch Valerie W
The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease.
Cancer 2002;95(1):119-26.
2002: Hortobagyi Gabriel N; Kris Mark G
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
Seminars in oncology 2002;29(3 Suppl 12):1-3.
2002: Ranson Malcolm; Hammond Lisa A; Ferry David; Kris Mark; Tullo Andrew; Murray Philip I; Miller Vince; Averbuch Steve; Ochs Judy; Morris Charles; Feyereislova Andrea; Swaisland Helen; Rowinsky Eric K
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2240-50.
2002: Martin Jocelyne; Ginsberg Robert J; Venkatraman Ennapadam S; Bains Manjit S; Downey Robert J; Korst Robert J; Kris Mark G; Rusch Valerie W
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):1989-95.
2002: Azzoli Christopher G; Krug Lee M; Miller Vincent A; Kris Mark G; Mass Robert
Trastuzumab in the treatment of non-small cell lung cancer.
Seminars in oncology 2002;29(1 Suppl 4):59-65.
2001: Kris M G; Azzoli C G
Chemotherapy for early stage non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 3():S49-52.
2001: Ettinger D S; Kris M G;
NCCN: Non-small cell lung cancer.
Cancer control : journal of the Moffitt Cancer Center 2001;8(6 Suppl 2):22-31.
2001: Martin J; Ginsberg R J; Abolhoda A; Bains M S; Downey R J; Korst R J; Weigel T L; Kris M G; Venkatraman E S; Rusch V W
Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy.
The Annals of thoracic surgery 2001;72(4):1149-54.
2001: Kawahara M; Kris M G; Green M; Kunitoh H
New drug and multimodality combinations in the treatment of advanced non--small cell lung cancer.
Seminars in oncology 2001;28(3 Suppl 9):1-4.
2001: Laurie S A; Pfister D G; Kris M G; Tong W P; Chronowski G; Pisters K M; Heelan R T; Sirotnak F M
Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):501-9.
2001: Sharma S; White D; Imondi A R; Placke M E; Vail D M; Kris M G
Development of inhalational agents for oncologic use.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1839-47.
2001: Shepherd F A; Fossella F V; Lynch T; Armand J P; Rigas J R; Kris M G
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.
Seminars in oncology 2001;28(1 Suppl 2):4-9.
2001: Kris M G; Manegold C
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update.
Seminars in oncology 2001;28(1 Suppl 2):1-3.
2000: Sirotnak F M; Zakowski M F; Miller V A; Scher H I; Kris M G
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4885-92.
2000: Sirotnak F M; Wendel H G; Bornmann W G; Tong W P; Miller V A; Scher H I; Kris M G
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3705-12.
2000: Krug L M; Ng K K; Kris M G; Miller V A; Tong W; Heelan R T; Leon L; Leung D; Kelly J; Grant S C; Sirotnak F M
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3493-8.
2000: Fossella F V; DeVore R; Kerr R N; Crawford J; Natale R R; Dunphy F; Kalman L; Miller V; Lee J S; Moore M; Gandara D; Karp D; Vokes E; Kris M; Kim Y; Gamza F; Hammershaimb L
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2354-62.
2000: Laurie S A; Kris M G
Single-agent docetaxel (Taxotere) in the treatment of advanced non small-cell lung cancer: clinical concepts and commentary.
Clinical lung cancer 2000;1 Suppl 1():S5-9.
2000: Miller V A; Kris M G
Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Seminars in oncology 2000;27(2 Suppl 3):3-10.
2000: Rosenzweig K E; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling C C; Armstrong J; Ginsberg R; Kris M G; Raben A; Leibel S
Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
Cancer journal (Sudbury, Mass.) 2000;6(2):82-7.
2000: Miller V A; Krug L M; Ng K K; Pizzo B; Perez W; Heelan R T; Kris M G
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1346-50.
2000: Miller V A; Ng K K; Krug L M; Perez W; Pizzo B; Heelan R T; Kris M G
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
Cancer 2000;88(5):1045-50.
2000: Pisters K M; Ginsberg R J; Giroux D J; Putnam J B; Kris M G; Johnson D H; Roberts J R; Mault J; Crowley J J; Bunn P A
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team.
The Journal of thoracic and cardiovascular surgery 2000;119(3):429-39.
2000: Krug L M; Miller V A; Kalemkerian G P; Kraut M J; Ng K K; Heelan R T; Pizzo B A; Perez W; McClean N; Kris M G
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):227-8.
1999: Parekh K; Rusch V; Kris M
The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia.
Cancer 1999;86(9):1720-3.
1999: Krug L M; Grant S C; Miller V A; Ng K K; Kris M G
Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination.
Seminars in oncology 1999;26(5 Suppl 15):55-61.
1999: Dickler M N; Ragupathi G; Liu N X; Musselli C; Martino D J; Miller V A; Kris M G; Brezicka F T; Livingston P O; Grant S C
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2773-9.
1999: Ng K K; Kris M G; Ginsberg R J; Heelan R T; Pisters K M; Miller V A; Grant S C; Bains M; Rusch V; Rosenzweig K E; Martini N
Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma.
Cancer 1999;86(7):1189-97.
1999: Gralla R J; Osoba D; Kris M G; Kirkbride P; Hesketh P J; Chinnery L W; Clark-Snow R; Gill D P; Groshen S; Grunberg S; Koeller J M; Morrow G R; Perez E A; Silber J H; Pfister D G
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2971-94.
1999: Kris M G; Millward M
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Seminars in oncology 1999;26(3 Suppl 10):1-2.
1999: Grant S C; Kris M G; Houghton A N; Chapman P B
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1319-23.
1999: Rigas J R; Kris M G; Miller V A; Pisters K M; Heelan R T; Grant S C; Fennelly D W; Chou T C; Sirotnak F M
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):601-3.
1999: Hollen P J; Gralla R J; Kris M G; Eberly S W; Cox C
Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS).
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999;7(3):140-8.
1999: Pizzo B A; Pisters K M; Miller V A; Grant S C; Baltzer L; Hinckley L; Kris M G
Oral cisapride for the control of delayed vomiting following high-dose cisplatin.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999;7(1):44-6.
1999: Navari R M; Reinhardt R R; Gralla R J; Kris M G; Hesketh P J; Khojasteh A; Kindler H; Grote T H; Pendergrass K; Grunberg S M; Carides A D; Gertz B J
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
The New England journal of medicine 1999;340(3):190-5.
1999: Martini N; Rusch V W; Bains M S; Kris M G; Downey R J; Flehinger B J; Ginsberg R J
Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer.
The Journal of thoracic and cardiovascular surgery 1999;117(1):32-6; discussion 37-8.
1998: Kindler H L; Kris M G; Smith I E; Miller V A; Grant S C; Krebs J B; Ross G A; Slevin M L
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
American journal of clinical oncology 1998;21(5):438-41.
1998: Demetri G D; Kris M; Wade J; Degos L; Cella D
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3412-25.
1998: Whitmore J B; Kris M G; Hesketh P J; Grote T H; DuBois D M; Cramer M B; Hahne W F
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(5):473-8.
1998: Kris M G
What does chemotherapy have to offer patients with advanced-stage non-small cell lung cancer?
Seminars in oncology 1998;25(3 Suppl 8):1-4.
1998: De Mulder P H; Roila F; Kris M G; Marty M M
Consensus regarding multiple day and rescue antiemetic therapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(3):248-52.
1998: Kris M G; Roila F; De Mulder P H; Marty M
Delayed emesis following anticancer chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(3):228-32.
1998: Nolte M J; Berkery R; Pizzo B; Baltzer L; Grossano D; Lucarelli C D; Kris M G
Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):771-8.
1997: Miller V A; Ng K K; Grant S C; Kindler H; Pizzo B; Heelan R T; von Roemeling R; Kris M G
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(12):1269-71.
1997: Hollen P J; Gralla R J; Cox C; Eberly S W; Kris M G
A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer.
Lung cancer (Amsterdam, Netherlands) 1997;18(2):119-36.
1997: Martini N; Kris M G; Ginsberg R J
The role of multimodality therapy in locoregional non-small cell lung cancer.
Surgical oncology clinics of North America 1997;6(4):769-91.
1997: Kris M G
Lung cancer cure, care, and cost: let the data be your guide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(9):3027-9.
1997: Kris M G; Miller V A; Ng K K; Grant S C
The development of docetaxel (Taxotere) in non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 14):S14-1-S14-4.
1997: Pisters K M; Kris M G; Bunn P A; Johnson D H; Ruckdeschel J C; Crowley J J; Ginsberg R J
Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team.
Seminars in oncology 1997;24(4 Suppl 12):S12-41-S12-44.
1997: Armstrong J; Raben A; Zelefsky M; Burt M; Leibel S; Burman C; Kutcher G; Harrison L; Hahn C; Ginsberg R; Rusch V; Kris M; Fuks Z
Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1997;44(1):17-22.
1997: Ballatori E; Roila F; De Angelis V; Ciccarese G; Palladino M A; Tonato M; Del Favero A; Herrstedt J; Dicato M; du Bois A; Hesketh P; Kris M; Gralla R J
Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(4):269-73.
1997: Kris M G; Radford J E; Pizzo B A; Inabinet R; Hesketh A; Hesketh P J
Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.
Journal of the National Cancer Institute 1997;89(11):817-8.
1997: Kris M G; Pendergrass K B; Navari R M; Grote T H; Nelson A M; Thomas V; Ferguson B B; Allman D S; Pizzo B A; Baker T W; Fernando I J; Chernoff S B
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):2135-8.
1997: Miller V A; Benedetti F M; Rigas J R; Verret A L; Pfister D G; Straus D; Kris M G; Crisp M; Heyman R; Loewen G R; Truglia J A; Warrell R P
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):790-5.
1997: Hesketh P J; Kris M G; Grunberg S M; Beck T; Hainsworth J D; Harker G; Aapro M S; Gandara D; Lindley C M
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):103-9.
1997: Miller V A; Rigas J R; Tong W P; Reid J R; Pisters K M; Grant S C; Heelan R T; Kris M G
Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;40(5):415-8.
1996: Pisters K M; Tyson L B; Tong W; Fleisher M; Miller V A; Grant S C; Pfister D G; Rigas J R; Densmore C L; Krol G; Heelan R T; Sirotnak F M; Bertino J R; Kris M G
High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(11):1819-24.
1996: Ettinger D S; Cox J D; Ginsberg R J; Komaki R; Kris M G; Livingston R B; Sugarbaker D J
NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.
Oncology (Williston Park, N.Y.) 1996;10(11 Suppl):81-111.
1996: Kris M G; Cubeddu L X; Gralla R J; Cupissol D; Tyson L B; Venkatraman E; Homesley H D
Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin.
Cancer 1996;78(10):2193-8.
1996: Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(8):2242-9.
1996: Rigas J R; Miller V A; Zhang Z F; Klimstra D S; Tong W P; Kris M G; Warrell R P
Metabolic phenotypes of retinoic acid and the risk of lung cancer.
Cancer research 1996;56(12):2692-6.
1996: Miller V A; Rigas J R; Benedetti F M; Verret A L; Tong W P; Kris M G; Gill G M; Loewen G R; Truglia J A; Ulm E H; Warrell R P
Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):471-5.
1996: Grant S C; Kostakoglu L; Kris M G; Yeh S D; Larson S M; Finn R D; Oettgen H F; Cheung N V
Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial.
European journal of nuclear medicine 1996;23(2):145-9.
1995: Rusch V; Klimstra D; Venkatraman E; Oliver J; Martini N; Gralla R; Kris M; Dmitrovsky E
Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.
Cancer research 1995;55(21):5038-42.
1995: Cleri L B; Kris M G; Tyson L B; Pisters K M; Clark R A; Gralla R J
Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.
Cancer 1995;76(5):774-8.
1995: Hesketh P J; Beck T; Uhlenhopp M; Kris M G; Hainsworth J D; Harker W G; Cohen J R; Lester E; Kessler J F; Griffen D
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):2117-22.
1995: Miller V A; Rigas J R; Pisters K M; Grant S C; Pfister D G; Heelan R T; Kris M G
Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy.
American journal of clinical oncology 1995;18(4):303-6.
1995: Miller V A; Rigas J R; Grant S C; Pisters K M; Kris M G
New chemotherapeutic agents for non-small cell lung cancer.
Chest 1995;107(6 Suppl):306S-311S.
1995: Rivera M P; Kris M G; Gralla R J; White D A
Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy.
American journal of clinical oncology 1995;18(3):245-50.
1995: Kris M G; Pisters K M; Ginsberg R J; Rigas J R; Miller V A; Grant S C; Gralla R J; Heelan R T; Martini N
Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2).
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 1():S47-57.
1995: Francis P A; Kris M G; Rigas J R; Grant S C; Miller V A
Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 1():S163-72.
1995: Miller V A; Rigas J R; Francis P A; Grant S C; Pisters K M; Venkatraman E S; Woolley K; Heelan R T; Kris M G
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Cancer 1995;75(4):968-72.
1995: Rigas J R; Francis P A; Miller V A; Tong W P; Roistacher N; Kris M G; Orazem J P; Young C W; Warrell R P
Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule.
Cancer chemotherapy and pharmacology 1995;35(6):483-8.
1995: Grant S C; Kris M G
New antineoplastic agents in lung cancer 1988-1993.
Cancer treatment and research 1995;72():323-47.
1994: Kris M G; Pisters K M; Hinkley L
Delayed emesis following anticancer chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1994;2(5):297-300.
1994: Pisters K M; Kris M G; Gralla R J; Hilaris B; McCormack P M; Bains M S; Martini N
Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer.
Journal of surgical oncology 1994;56(4):236-41.
1994: Hollen P J; Gralla R J; Kris M G; Cox C
Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS).
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1994;2(4):213-22.
1994: Tyson L B; Kris M G; Baltzer L; Pisters K M; Rigas J R; Clark R A
Randomized phase II trial comparing two versus three doses of ondansetron when used in combination with dexamethasone in patients receiving cisplatin > or = 100 mg/m2.
American journal of clinical oncology 1994;17(3):269-72.
1994: Francis P A; Rigas J R; Kris M G; Pisters K M; Orazem J P; Woolley K J; Heelan R T
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(6):1232-7.
1994: Kris M G; Grunberg S M; Gralla R J; Baltzer L; Zaretsky S A; Lifsey D; Tyson L B; Schmidt L; Hahne W F
Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(5):1045-9.
1994: Hollen P J; Gralla R J; Kris M G; Cox C; Belani C P; Grunberg S M; Crawford J; Neidhart J A
Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.
Cancer 1994;73(8):2087-98.
1994: Baltzer L; Kris M G; Tyson L B; Rigas J R; Pisters K M
The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin.
Cancer 1994;73(3):720-3.
1994: Kris M G
Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
Important advances in oncology 1994;():165-77.
1994: Miller V A; Rigas J R; Muindi J R; Tong W P; Venkatraman E; Kris M G; Warrell R P
Modulation of all-trans retinoic acid pharmacokinetics by liarozole.
Cancer chemotherapy and pharmacology 1994;34(6):522-6.
1993: Kris M G; Baltzer L; Pisters K M; Tyson L B
Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone.
Cancer 1993;72(11 Suppl):3436-42.
1993: Rigas J R; Francis P A; Muindi J R; Kris M G; Huselton C; DeGrazia F; Orazem J P; Young C W; Warrell R P
Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.
Journal of the National Cancer Institute 1993;85(23):1921-6.
1993: Baltzer L; Kris M G; Tyson L B; Rigas J R; Vreeland F; Pisters K M
Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
Cancer 1993;72(9):2695-9.
1993: Potanovich L M; Pisters K M; Kris M G; Tyson L B; Clark R A; Baltzer L; Gralla R J
Midazolam in patients receiving anticancer chemotherapy and antiemetics.
Journal of pain and symptom management 1993;8(8):519-24.
1993: Pisters K M; Kris M G; Gralla R J; Zaman M B; Heelan R T; Martini N
Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(9):1757-62.
1993: Martini N; Kris M G; Flehinger B J; Gralla R J; Bains M S; Burt M E; Heelan R; McCormack P M; Pisters K M; Rigas J R
Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.
The Annals of thoracic surgery 1993;55(6):1365-73; discussion 1373-4.
1993: Kris M G; Clark R A; Tyson L B; Hahne W F; Pisters K M; Gralla R J
Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.
American journal of clinical oncology 1993;16(1):77-80.
1993: Baselga J; Kris M G; Scher H I; Phillips M; Heelan R T
Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer.
Investigational new drugs 1993;11(1):85-6.
1993: Pisters K M; Kris M G; Tyson L B; Clark R A; Gralla R J
Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy.
Cancer 1993;71(1):226-30.
1993: Grant S C; Kris M G; Gralla R J; Clark R A; Tyson L B
Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy.
Cancer chemotherapy and pharmacology 1993;31(6):442-4.
1993: Kris M G; Tyson L B
Tropisetron (ICS 205-930): a selective 5-hydroxytryptamine antagonist.
European journal of cancer (Oxford, England : 1990) 1993;29A Suppl 1():S30-2.
1993: Grant S C; Kris M G; Young C W; Sirotnak F M
Edatrexate, an antifolate with antitumor activity: a review.
Cancer investigation 1993;11(1):36-45.
1993: Hollen P J; Gralla R J; Kris M G; Potanovich L M
Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).
European journal of cancer (Oxford, England : 1990) 1993;29A Suppl 1():S51-8.
1992: Rigas J R; Tong W P; Kris M G; Orazem J P; Young C W; Warrell R P
Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.
Cancer research 1992;52(23):6619-23.
1992: Rusch V W; Reuter V E; Kris M G; Kurie J; Miller W H; Nanus D M; Albino A P; Dmitrovsky E
Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer.
The Journal of thoracic and cardiovascular surgery 1992;104(5):1465-9.
1992: Kris M G
Rationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations.
Seminars in oncology 1992;19(4 Suppl 10):61-6.
1992: Kris M G
Phase II trials of ondansetron with high-dose cisplatin.
Seminars in oncology 1992;19(4 Suppl 10):23-7.
1992: Kris M G; Tyson L B; Clark R A; Gralla R J
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Cancer 1992;70(4 Suppl):1012-6.
1992: Grant S C; Kris M G
Phase II trials in small-cell lung cancer: shouldn't we be doing better?
Journal of the National Cancer Institute 1992;84(14):1058-9.
1992: Pisters K M; Kris M G; Tyson L B; Clark R A; Gralla R J
Dose-ranging trial of zacopride: the emetic antiemetic?
Journal of the National Cancer Institute 1992;84(9):717-8.
1992: Grant S C; Gralla R J; Kris M G; Orazem J; Kitsis E A
Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):484-98.
1992: Pisters K M; Kris M G
Management of nausea and vomiting caused by anticancer drugs: state of the art.
Oncology (Williston Park, N.Y.) 1992;6(2 Suppl):99-104.
1992: Rosenstein M; Armstrong J; Kris M; Shank B; Scher H; Fass D; Harrison L; Fuks Z; Leibel S
A reappraisal of the role of prophylactic cranial irradiation in limited small cell lung cancer.
International journal of radiation oncology, biology, physics 1992;24(1):43-8.
1992: Armstrong J G; Martini N; Kris M G; Harrison L B
Induction chemotherapy for non-small cell lung cancer with clinically evident mediastinal node metastases: the role of postoperative radiotherapy.
International journal of radiation oncology, biology, physics 1992;23(3):605-13.
1991: Armstrong J G; Rosenstein M M; Kris M G; Shank B M; Scher H I; Fass D E; Harrison L B; Leibel S A; Fuks Z Y
Twice daily thoracic irradiation for limited small cell lung cancer.
International journal of radiation oncology, biology, physics 1991;21(5):1269-74.
1991: Armstrong J; Shank B; Scher H; Gaynor J; Martini N; Kutcher J; Kris M
Limited small-cell lung cancer: do favorable short-term results predict ultimate outcome?
American journal of clinical oncology 1991;14(4):285-90.
1991: Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
The New England journal of medicine 1991;325(3):164-70.
1991: Rigas J R; Kris M G; Gralla R J; Heelan R T; Marks L D
Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
Investigational new drugs 1991;9(2):187-90.
1991: Berger M Z; Kris M G; Gralla R J; Marks L D; Potanovich L M; Dimaggio J J; Heelan R T
Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
American journal of clinical oncology 1991;14(2):124-6.
1991: Armstrong J G; Rosenstein M M; Scher H I; Fass D E; Zelefsky M J; Kris M G
Limited small cell lung cancer: prognostic significance of a complete response to the induction phase of chemotherapy followed by thoracic irradiation.
Radiology 1991;178(3):875-8.
1991: Divgi C R; Welt S; Kris M; Real F X; Yeh S D; Gralla R; Merchant B; Schweighart S; Unger M; Larson S M
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.
Journal of the National Cancer Institute 1991;83(2):97-104.
1991: Markman M; D'Acquisto R; Iannotti N; Kris M; Hakes T; Bajorin D; Bosl G; Reichman B; Casper E; Magill G
Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate.
Journal of cancer research and clinical oncology 1991;117(2):151-5.
1991: Gralla R J; Clark R A; Kris M G; Tyson L B
Methodology in anti-emetic trials.
European journal of cancer (Oxford, England : 1990) 1991;27 Suppl 1():S5-8; discussion S22.
1990: Dalmau J; Furneaux H M; Gralla R J; Kris M G; Posner J B
Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis.
Annals of neurology 1990;27(5):544-52.
1989: Tyson L B; Gralla R J; Kris M G; Young C W; Clark R A
Dose-ranging antiemetic trial of high-dose oral metoclopramide.
American journal of clinical oncology 1989;12(3):239-43.
1989: Clark R A; Tyson L B; Gralla R J; Kris M G
Antiemetic therapy: management of chemotherapy-induced nausea and vomiting.
Seminars in oncology nursing 1989;5(2 Suppl 1):53-7.
1989: Kris M G; D'Acquisto R W; Gralla R J; Burke M T; Marks L D; Fanucchi M P; Heelan R T
Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
American journal of clinical oncology 1989;12(1):24-6.
1989: Kris M G; Gralla R J; Tyson L B; Clark R A; Cirrincione C; Groshen S
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(1):108-14.
1989: Kris M G; Gralla R J; Clark R A; Tyson L B
Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin.
Journal of the National Cancer Institute 1989;81(1):42-6.
1988: Kris M G; Kinahan J J; Gralla R J; Fanucchi M P; Wertheim M S; O'Connell J P; Marks L D; Williams L; Farag F; Young C W
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Cancer research 1988;48(19):5573-9.
1988: Gralla R J; Kris M G
Chemotherapy in non-small cell lung cancer: results of recent trials.
Seminars in oncology 1988;15(3 Suppl 4):2-5.
1988: Kris M G; Gralla R J; Clark R A; Tyson L B; Groshen S
Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C: a randomized trial with placebo in patients receiving cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(4):663-8.
1988: Kris M G; Gralla R J; Clark R A; Tyson L B
Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(4):659-62.
1988: Martini N; Kris M G; Gralla R J; Bains M S; McCormack P M; Kaiser L R; Burt M E; Zaman M B
The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0).
The Annals of thoracic surgery 1988;45(4):370-9.
1988: Shum K Y; Kris M G; Gralla R J; Burke M T; Marks L D; Heelan R T
Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(3):446-50.
1988: Gralla R J; Kris M G; Tyson L B; Clark R A
Controlling emesis in patients receiving cancer chemotherapy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1988;108():89-101.
1988: Kris M G
Peaks, valleys, and plateaus in small cell lung cancer.
Cancer investigation 1988;6(6):743-4.
1988: Scher H; Gralla R; Linares L; Kris M; Heelan R; Shank B
Preliminary results of combination chemotherapy and sequential accelerated fractionation radiation therapy in limited-stage small cell carcinoma of the lung. Evaluation of measures for reduction of toxicity and effect on complete response rate.
Antibiotics and chemotherapy 1988;41():184-9.
1987: Kris M G; Gralla R J; Clark R A; Tyson L B; Groshen S
Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial.
Cancer 1987;60(11):2816-22.
1987: Kris M G; Gralla R J; Martini N; Stampleman L V; Burke M T
Preoperative and adjuvant chemotherapy in locally advanced non-small cell lung cancer.
The Surgical clinics of North America 1987;67(5):1051-9.
1987: Kris M G; Gralla R J; Burke M T; Fiore J J; Kelsen D P; Marks L D; Heelan R T
Phase II trial of esorubicin in patients with advanced non-small cell lung cancer.
Cancer treatment reports 1987;71(7-8):783-4.
1987: Kris M G; Gralla R J; Burke M T; Berkowitz L D; Marks L D; Kelsen D P; Heelan R T
Phase II trial of oral piritrexim (BW301U) in patients with stage III non-small cell lung cancer.
Cancer treatment reports 1987;71(7-8):763-4.
1987: White D A; Kris M G; Stover D E
Bronchoalveolar lavage cell populations in bleomycin lung toxicity.
Thorax 1987;42(7):551-2.
1987: White D A; Schwartzberg L S; Kris M G; Bosl G J
Acute chest pain syndrome during bleomycin infusions.
Cancer 1987;59(9):1582-5.
1987: Gralla R J; Tyson L B; Kris M G; Clark R A
The management of chemotherapy-induced nausea and vomiting.
The Medical clinics of North America 1987;71(2):289-301.
1986: O'Connell J P; Kris M G; Gralla R J; Groshen S; Trust A; Fiore J J; Kelsen D P; Heelan R T; Golbey R B
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(11):1604-14.
1986: Kris M G; Gralla R J; Wertheim M S; Kelsen D P; O'Connell J P; Burke M T; Fiore J J; Cibas I R; Heelan R T
Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.
Cancer treatment reports 1986;70(9):1091-6.
1986: Kris M G; O'Connell J P; Gralla R J; Wertheim M S; Parente R M; Schiff P B; Young C W
Phase I trial of taxol given as a 3-hour infusion every 21 days.
Cancer treatment reports 1986;70(5):605-7.
1986: Kris M G; Yeh S D; Gralla R J; Young C W
Simultaneous estimation of liquid and solid gastric emptying using radiolabelled egg and water in supine normal subjects.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1986;13(6):629-31.
1985: Tyson L B; Gralla R J; Clark R A; Kris M G; Bordin L A; Bosl G J
Phase 1 trial of levonantradol in chemotherapy-induced emesis.
American journal of clinical oncology 1985;8(6):528-32.
1985: Kris M G; Gralla R J; Clark R A; Tyson L B; Fiore J J; Kelsen D P; Groshen S
Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.
Cancer treatment reports 1985;69(11):1257-62.
1985: Kris M G; Gralla R J; Clark R A; Tyson L B; O'Connell J P; Wertheim M S; Kelsen D P
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(10):1379-84.
1985: Kris M G; Gralla R J; Kelsen D P; Casper E S; Burke M T; Fiore J J; Cibas I R; Heelan R T
Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
American journal of clinical oncology 1985;8(5):377-9.
1985: Kris M G; Gralla R J; Kalman L A; Kelsen D P; Casper E S; Burke M T; Groshen S; Cibas I R; Bagin R; Heelan R T
Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment.
Cancer treatment reports 1985;69(4):387-95.
1985: Kris M G; Gralla R J; Kelsen D P; Casper E S; Burke M T; Fiore J J; Cibas I R; Heelan R T
Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment.
Chest 1985;87(3):368-72.
1985: Kris M G; Gralla R J; Tyson L B; Clark R A; Kelsen D P; Reilly L K; Groshen S; Bosl G J; Kalman L A
Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.
Cancer 1985;55(3):527-34.
1985: Kris M G; Mertelsmann R; Jhanwar S; Chaganti R; Szatrowski T H; Gee T S; Arlin Z; Kempin S; Benedetto P; Clarkson B
Relationship of Auer rods and chromosome findings to outcome in eighty-nine adults with acute nonlymphoblastic leukemia.
Leukemia research 1985;9(10):1231-5.
1984: Kris M G; Pablo D; Gralla R J; Burke M T; Prestifilippo J; Lewin D
Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy.
Cancer treatment reports 1984;68(7-8):1029-31.
1984: Gralla R J; Tyson L B; Bordin L A; Clark R A; Kelsen D P; Kris M G; Kalman L B; Groshen S
Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol.
Cancer treatment reports 1984;68(1):163-72.
1983: Kalman L A; Gralla R J; Casper E S; Kris M G; Gordon C; Woodcock T M
Phase I trial of PCNU.
Cancer treatment reports 1983;67(11):1027-9.
1983: Kalman L A; Stoopler M B; Casper E S; Kelsen D P; Kris M G; Gralla R J
Phase II trial of PCNU in non-small cell lung cancer.
Cancer treatment reports 1983;67(9):837.
1983: Kris M G; Tyson L B; Gralla R J; Clark R A; Allen J C; Reilly L K
Extrapyramidal reactions with high-dose metoclopramide.
The New England journal of medicine 1983;309(7):433-4.
1983: Kris M G; Gralla R J; Tyson L B; Clark R A
Antiemetics and cytotoxic drugs.
British medical journal (Clinical research ed.) 1983;287(6388):363-4.
1983: Kalman L A; Kris M G; Gralla R J; Kelsen D P; Casper E S; Heelan R T; Wittes R E
Phase II trial of 4'-epi-doxorubicin in patients with non-small cell lung cancer.
Cancer treatment reports 1983;67(6):591-2.
1982: Moseley R H; Kris M G; Einzig A; West R; Gee T S; Armstrong D
Respiratory alkalosis and abdominal pain heralding Candida hepatitis: occurrence in patients with acute leukemia in remission.
Archives of internal medicine 1982;142(8):1495-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Mark Kris

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Mark Kris (preview)

All Publications